Get the Stockscreener App
71.92
1.30%
-0.91
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $71.92, with a volume of 2.05M.
It is down -1.30% in the last 24 hours and down -0.77% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$72.83
Open:
$71.565
24h Volume:
2.05M
Relative Volume:
0.38
Market Cap:
$111.50B
Revenue:
$54.98B
Net Income/Loss:
$7.77B
P/E Ratio:
28.88
EPS:
2.49
Net Cash Flow:
$9.14B
1W Performance:
+2.09%
1M Performance:
-0.77%
6M Performance:
+7.22%
1Y Performance:
-7.87%
1-Day Range:
$71.28
$72.15
1-Week Range:
$69.97
$73.20
52-Week Range:
$61.24
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
71.91 | 220.00B | 54.98B | 7.77B | 9.14B | 2.49 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
AstraZeneca (AZN) Highlights Encouraging Enhertu Results in Breast Cancer Trial | AZN Stock News - GuruFocus
Breast Cancer Growth Slowed by 14 Months in New AstraZeneca Drug Study - Bloomberg
AstraZeneca (AZN) Highlights Success in Breast Cancer Trial with Camizestrant | AZN Stock News - GuruFocus
AstraZeneca: promising results for Imfinzi in gastric cancer - marketscreener.com
AstraZeneca: camizestrant effective in breast cancer - marketscreener.com
AstraZeneca Pharma India Share Price Jumps Post Q4 Profit, Margin Growth - NDTV Profit
PRESS DIGEST- Financial TimesJune 2 - marketscreener.com
AstraZeneca's (AZN) DATROWAY Shows Promise in Lung Cancer Trials | AZN Stock News - GuruFocus
AstraZeneca (AZN) Reports Positive Phase III Trial Results for IMFINZI | AZN Stock News - GuruFocus
AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant | AZN Stock News - GuruFocus
AstraZeneca (AZN): ENHERTU Demonstrates Significant Survival Boost in Gastric Cancer Trial | AZN Stock News - GuruFocus
AstraZeneca breast cancer medicine slows disease by over six months - The Economic Times
Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk - marketscreener.com
A funding flashpoint, Pfizer’s $1B poster and AstraZeneca advertising - BioPharma Dive
AstraZeneca drug could help keep a common breast cancer at bay - BioPharma Dive
IMFINZI (Durvalumab) Regimen Reduced Risk Of Progression, Recurrence Or Death By 29% In Early-Stage Gastric Cancer Versus Chemotherapy Alone In Matterhorn Phase III Trial - marketscreener.com
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds - marketscreener.com
AstraZeneca Breast Cancer Pill Slows Disease by Over Six Months - Bloomberg
AstraZeneca Reaches $51 Million Settlement in Pay-for-Delay Suit - Bloomberg Law News
AstraZeneca agrees to $51 million settlement in Seroquel antitrust class action - Reuters
Danaher Partners With AstraZeneca to Support Precision Medicine - Yahoo Finance
AstraZeneca - Britannica
AstraZeneca, Danaher to Develop New Precision Medicine Diagnostic Tools - marketscreener.com
Barclays Remains Upbeat on AstraZeneca, Expects US Conference to Highlight Breast Cancer Franchise - marketscreener.com
AstraZeneca gets CDSCO nod for new indications of Benralizumab, Osimertinib in India - Medical Dialogues
Danaher Corporation (DHR) Launches Partnership with AstraZeneca PLC (AZN) to Scale Next-Gen Precision Medicine Tests - Yahoo Finance
AstraZeneca Inks $51.4M Settlement In Pay-For-Delay Case - Law360
Danaher in partnership with AstraZeneca for diagnostic tests for precision medicine (DHR:NYSE) - Seeking Alpha
Danaher partners with AstraZeneca on AI diagnostics By Investing.com - Investing.com Nigeria
Bispecific Antibody Drug Conjugates Clinical Trials Bispecific ADC Market Size Insight - GlobeNewswire Inc.
RNA Targeting Small Molecule Drug Discovery Research Report 2025 - GlobeNewswire Inc.
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - Yahoo Finance
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy? - Yahoo Finance
Transcript : AstraZeneca PLCSpecial Call - marketscreener.com
AstraZeneca and Global Transparency - AstraZeneca
Ethics and Compliance - AstraZeneca
Nature - AstraZeneca
Inclusion and diversity - AstraZeneca
Community investment - AstraZeneca
AstraZeneca (AZN) Collaborates on Major AI Infrastructure in Swe - GuruFocus
AstraZeneca PLC (AZN) Trial: Airsupra Cuts Severe Asthma Risk by 47% - MSN
AstraZeneca (AZN) Executive Joins Rapid Micro Biosystems' Board | AZN Stock News - GuruFocus
AstraZeneca (AZN) Gains EU Panel Support for Imfinzi in Bladder Cancer - GuruFocus
AstraZeneca (AZN) Nears EU Approval for Imfinzi in Bladder Cance - GuruFocus
AstraZeneca wins EU backing for Imfinzi in bladder cancer - Seeking Alpha
AstraZeneca Gains Positive Opinion for Imfinzi's Bladder Cancer Indication in EU - marketscreener.com
AstraZeneca: CHMP gives positive opinion for Imfinzi - marketscreener.com
EU recommends AstraZeneca bladder cancer treatment for approval - Sharecast.com
AstraZeneca Plc Imfinzi recommended for EU approval in bladder cancer - DirectorsTalk Interviews
AstraZeneca's Imfinzi Wins EU Approval Recommendation for Bladder Cancer - marketscreener.com
AstraZeneca Says Imfinzi Recommended In EU For Bladder Cancer - marketscreener.com
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):